Telix's BiPASS Program Gains FDA Fast Track for Pre-Biopsy Prostate Cancer Imaging
Event summary
- Telix's BiPASS program received FDA Fast Track designation for evaluating 68Ga-PSMA-PET imaging combined with MRI in pre-biopsy prostate cancer diagnosis.
- The designation aims to address the unmet need for reducing unnecessary biopsies, with up to 75% of current biopsies yielding negative results.
- Telix completed enrollment in the Phase 3 BiPASS study and is planning an NDA submission, potentially broadening access to 68Ga-PSMA-PET imaging.
- Previous studies (PRIMARY and PRIMARY2) showed that combining 68Ga-PSMA-PET with MRI can improve detection of clinically significant prostate cancer and reduce unnecessary biopsies by nearly 50%.
- Illuccix and Gozellix are currently approved for PET imaging of PSMA-positive lesions but remain investigational in the pre-biopsy setting.
The big picture
Telix's FDA Fast Track designation for BiPASS underscores the growing emphasis on non-invasive diagnostic tools in oncology. The program aligns with broader industry trends toward precision medicine and theranostics, which pair diagnostics with targeted therapies. With over three million prostate biopsies performed annually and a high rate of negative results, the potential to reduce unnecessary procedures represents a significant market opportunity. Telix's strategic focus on expanding its diagnostic portfolio could enhance its position in the competitive radiopharmaceutical landscape.
What we're watching
- Regulatory Pathway
- The pace at which Telix advances BiPASS toward an NDA submission and secures FDA approval will determine the program's commercial viability.
- Market Adoption
- Whether the combination of 68Ga-PSMA-PET and MRI can gain widespread acceptance among clinicians as a standard pre-biopsy diagnostic tool.
- Competitive Dynamics
- How Telix's BiPASS program positions against existing and emerging diagnostic technologies in the prostate cancer space.
Related topics
